Sign in with Google
bullish
2023 High Conviction Idea: Cipla (CIPLA IN)- Complex Generics and India Business to Drive Growth
Tina has highlighted this Insight as a Top Pick
509 Views08 Nov 2022 15:28
SUMMARY
- Cipla Ltd (CIPLA IN) is a strong play in Indian generic pharmaceutical industry, due to its niche and differentiated respiratory and peptide injectable portfolio, which has less competition.
- The company has launched couple of complex respiratory products in the US market, which has accelerated its revenue growth. Multiple high-value launches are also lined up for this year.
- Cipla’s India business is on a strong footing, led by core portfolio tailwind in prescription and trade generics businesses. Q2FY23 marked the sixth consecutive quarter of market beating growth.
Related Insights
More »Loading
Trending Collections
More »Loading
Trending Insights
More »Loading
Top Unpaywalled Insights
More »Loading
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- 2023 High Conviction Update: Cipla (CIPLA IN)- Stellar Q1FY24 Performance; Margin Guidance Raised29 Jul 2023
- 2023 High Conviction Update: Cipla (CIPLA IN)- Strong US Business Drove Q4 Result Amid Uncertainty16 May 2023
- 2023 High Conviction Update: Cipla (CIPLA IN)- Strong Traction Continued in Q3; Record High US Sales29 Jan 2023
- 2023 High Conviction Idea: Cipla (CIPLA IN)- Complex Generics and India Business to Drive Growth08 Nov 2022
x